Replimune Group (NASDAQ:REPL) Stock Price Down 5.2% - Here's What Happened

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report)'s share price was down 5.2% on Friday . The stock traded as low as $11.87 and last traded at $11.85. Approximately 1,349,038 shares traded hands during mid-day trading, an increase of 44% from the average daily volume of 937,693 shares. The stock had previously closed at $12.50.

Analysts Set New Price Targets

Several equities research analysts recently commented on REPL shares. HC Wainwright reiterated a "buy" rating and issued a $22.00 price objective on shares of Replimune Group in a research report on Thursday, July 3rd. Cantor Fitzgerald initiated coverage on shares of Replimune Group in a research note on Friday, June 20th. They issued an "overweight" rating for the company. JPMorgan Chase & Co. lifted their price target on shares of Replimune Group from $16.00 to $19.00 and gave the stock an "overweight" rating in a report on Wednesday. Finally, Piper Sandler raised their target price on shares of Replimune Group from $14.00 to $22.00 and gave the stock an "overweight" rating in a research report on Monday, June 2nd. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $21.00.

Replimune Group Price Performance

The company has a market capitalization of $953.14 million, a PE ratio of -4.01 and a beta of 0.61. The company has a current ratio of 7.95, a quick ratio of 7.95 and a debt-to-equity ratio of 0.17. The company's 50 day moving average price is $9.44 and its 200-day moving average price is $10.49.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its earnings results on Thursday, May 22nd. The company reported ($0.82) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same quarter in the previous year, the business posted ($0.25) earnings per share. On average, sell-side analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Insider Activity

In other Replimune Group news, CAO Andrew Schwendenman sold 3,287 shares of Replimune Group stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $8.05, for a total transaction of $26,460.35. Following the transaction, the chief accounting officer directly owned 68,284 shares of the company's stock, valued at $549,686.20. The trade was a 4.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Konstantinos Xynos sold 7,952 shares of the company's stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total transaction of $64,093.12. Following the sale, the insider directly owned 146,933 shares of the company's stock, valued at approximately $1,184,279.98. This trade represents a 5.13% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 74,907 shares of company stock worth $603,655. Insiders own 8.80% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of REPL. Sterling Capital Management LLC lifted its holdings in Replimune Group by 364.5% in the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock worth $26,000 after acquiring an additional 1,655 shares during the last quarter. US Bancorp DE increased its position in Replimune Group by 582.6% in the first quarter. US Bancorp DE now owns 4,594 shares of the company's stock worth $45,000 after buying an additional 3,921 shares during the period. Tower Research Capital LLC TRC lifted its stake in Replimune Group by 696.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company's stock valued at $82,000 after buying an additional 5,922 shares during the last quarter. Aster Capital Management DIFC Ltd grew its position in shares of Replimune Group by 8,798.9% during the fourth quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company's stock worth $100,000 after acquiring an additional 8,183 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Replimune Group by 106.2% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,410 shares of the company's stock worth $111,000 after acquiring an additional 5,876 shares during the period. Hedge funds and other institutional investors own 92.53% of the company's stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.